{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:43:26Z","timestamp":1787507006439,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Oculopharyngeal muscular dystrophy (OPMD) is a late-onset autosomal dominant myopathy, caused by a (GCN)n\/polyalanine repeat expansion in the\n                      <jats:italic>PABPN1<\/jats:italic>\n                      gene. In Israel, OPMD is particularly prevalent among individuals of Jewish Bukharian descent due to a (GCN)13 repeat expansion. In this retrospective study, we collected genetic and clinical data of OPMD patients who visited the Israeli reference clinic from its opening in 2022 through September 2025 and were enrolled in the Israeli OPMD registry (IsrO-PMD).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 102 Jewish individuals with OPMD symptoms and a confirmed molecular diagnosis were identified (52 males, 51.0%). The heterozygous (GCN)13 repeat allele (10\/13 genotype) was found in 95 patients (93.1%), of whom 89 (93.7%) were of Bukharian descent, five (5.6%) were of Bulgarian origin, and a single patient was from Georgia. In this 10\/13 genotype group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200995), initial symptoms were dysphagia and ptosis, which occurred at a similar mean age of 53.0\u2009\u00b1\u20098.3 and 53.9\u2009\u00b1\u20097.2 years, respectively. Symptoms of limb muscle weakness occurred significantly later, at a mean age of 57.9\u2009\u00b1\u200910.2\u2009years. Overall, the onset of symptoms occurred approximately 4\u2009years earlier in females (48.9\u2009\u00b1\u20097.9,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200948) than in males (52.6\u2009\u00b1\u20097.1,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200947), and this difference was statistically significant (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02). However, the difference did not reach significance when calculated for each of the three symptoms separately. On evaluation, at a mean age of 61.6\u2009\u00b1\u200910.7\u2009years, dysphagia was present in 92\/95 (96.8%) of patients, ptosis in 85\/95 (89.5%), and limb muscle weakness in 56\/95 (58.9%) of cases, most notably of hip flexion and abduction. Different genotypes were detected in seven patients: Three of Bukharian descent were homozygous for (GCN)13 repeats, three of Karaite descent were homozygous for (GCN)11 repeats, and one of Tunisian origion was heterozygous for (GCN)15 repeats (10\/15 genotype).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>While most OPMD patients in Israel are of Jewish Bukharian descent, patients from other origins were also identified. Dysphagia and ptosis are the common initial symptoms, and overall, the onset of symptoms was reportedly earlier in females. Proximal muscle weakness becomes common with disease progression. Further studies are required to delineate genotype-phenotype correlations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04313-6","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:32:18Z","timestamp":1779190338000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The genetic and clinical characteristics of oculopharyngeal muscular dystrophy patients in Israel"],"prefix":"10.1186","volume":"21","author":[{"given":"Merav","family":"Ben-David","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lior","family":"Greenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Nikitn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Zvulunov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagit","family":"Charas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naama","family":"Divon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tali","family":"Barkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odelia","family":"Chorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haike","family":"Reznik-Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofira","family":"Zloto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limor","family":"Benyamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahar","family":"Shelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4633-1481","authenticated-orcid":false,"given":"Amir","family":"Dori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"issue":"1","key":"4313_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1055\/s-2008-1040826","volume":"19","author":"B Brais","year":"1999","unstructured":"Brais B, Rouleau GA, Bouchard JP, Fardeau M, Tom\u00e9 FM. Oculopharyngeal muscular dystrophy. Semin Neurol. 1999;19(1):59\u201366.","journal-title":"Semin Neurol"},{"issue":"4","key":"4313_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1212\/WNL.0000000000003554","volume":"88","author":"P Richard","year":"2017","unstructured":"Richard P, Trollet C, Stojkovic T, de Becdelievre A, Perie S, Pouget J, et al. Correlation between PABPN1 genotype and disease severity in oculopharyngeal muscular dystrophy. Neurology. 2017, Jan, 24;88(4):359\u201365.","journal-title":"Neurology"},{"key":"4313_CR3","unstructured":"Trollet C, Boulinguiez A, Roth F, Stojkovic T, Butler-Browne G, Evangelista T, et al. Oculopharyngeal muscular dystrophy. in:. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors GeneReviews\u00ae [Internet]. Seattle (WA), Seattle: University of Washington; 1993. cited 2025 Mar 28]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1126\/."},{"key":"4313_CR4","doi-asserted-by":"crossref","unstructured":"Kroon RHMJM, Kalf JG, de Swart Bjm, van der Sluijs Bm, Glennon JC, Raz V, et al. Longitudinal assessment of strength, Functional capacity, oropharyngeal function, and quality of life in oculopharyngeal muscular dystrophy. Neurology. 2021, Oct 11;97(15):e1475\u201383.","DOI":"10.1212\/WNL.0000000000012640"},{"issue":"12","key":"4313_CR5","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.nmd.2017.09.010","volume":"27","author":"van der Sluijs Bm","year":"2017","unstructured":"van der Sluijs Bm, Lassche S, Knuiman GJ, Kusters B, Heerschap A, Hopman M, et al. Involvement of pelvic girdle and proximal leg muscles in early oculopharyngeal muscular dystrophy. Neuromuscul Disord NMD. 2017, Dec;27(12):1099\u2013105.","journal-title":"Neuromuscul Disord NMD"},{"issue":"2","key":"4313_CR6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/mus.26888","volume":"62","author":"JD Brisson","year":"2020","unstructured":"Brisson JD, Gagnon C, Brais B, C\u00f4t\u00e9 I, Mathieu J. A study of impairments in oculopharyngeal muscular dystrophy. Muscle Nerve. 2020, Aug;62(2):201\u201307.","journal-title":"Muscle Nerve"},{"issue":"2","key":"4313_CR7","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/ng0298-164","volume":"18","author":"B Brais","year":"1998","unstructured":"Brais B, Bouchard JP, Xie YG, Rochefort DL, Chr\u00e9tien N, Tom\u00e9 FMS, et al. Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat Genet. 1998, Feb, 1;18(2):164\u201367.","journal-title":"Nat Genet"},{"issue":"4","key":"4313_CR8","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00439-004-1235-2","volume":"116","author":"DO Robinson","year":"2005","unstructured":"Robinson DO, Hammans SR, Read SP, Sillibourne J. Oculopharyngeal muscular dystrophy (OPMD): analysis of the PABPN1 gene expansion sequence in 86 patients reveals 13 different expansion types and further evidence for unequal recombination as the mutational mechanism. Hum Genet. 2005, Mar;116(4):267\u201371.","journal-title":"Hum Genet"},{"issue":"2","key":"4313_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3233\/JND-140060","volume":"2","author":"P Richard","year":"2015","unstructured":"Richard P, Trollet C, Gidaro T, Demay L, Brochier G, Malfatti E, et al. PABPN1 (GCN)11 as a dominant allele in oculopharyngeal muscular dystrophy -consequences in clinical diagnosis and genetic counselling. J Neuromuscul Dis. 2015, Jun, 4;2(2):175\u201380.","journal-title":"J Neuromuscul Dis"},{"issue":"4","key":"4313_CR10","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1017\/S0317167100018588","volume":"41","author":"L Jouan","year":"2014","unstructured":"Jouan L, Rocheford D, Szuto A, Carney E, David K, Dion PA, et al. An 18 alanine repeat in a severe form of oculopharyngeal muscular dystrophy. Can J Neurol Sci J Can Sci Neurol. 2014, Jul;41(4):508\u201311.","journal-title":"Can J Neurol Sci J Can Sci Neurol"},{"issue":"1\u20134","key":"4313_CR11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1159\/000072861","volume":"100","author":"B Brais","year":"2003","unstructured":"Brais B. Oculopharyngeal muscular dystrophy: a late-onset polyalanine disease. Cytogenet Genome Res. 2003;100(1\u20134):252\u201360.","journal-title":"Cytogenet Genome Res"},{"issue":"11","key":"4313_CR12","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.nmd.2011.06.003","volume":"21","author":"DO Robinson","year":"2011","unstructured":"Robinson DO, Hilton-Jones D, Mansfield D, Hildebrand GD, Marks S, Mechan D, et al. Two cases of oculopharyngeal muscular dystrophy (OPMD) with the rare PABPN1 c.35G & >C; p.Gly12Ala point mutation. Neuromuscul Disord NMD. 2011, Nov;21(11):809\u201311.","journal-title":"Neuromuscul Disord NMD"},{"issue":"34","key":"4313_CR13","doi-asserted-by":"publisher","first-page":"22803","DOI":"10.1074\/jbc.M109.018226","volume":"284","author":"U K\u00fchn","year":"2009","unstructured":"K\u00fchn U, G\u00fcndel M, Knoth A, Kerwitz Y, R\u00fcdel S, Wahle E. Poly(A) tail length is controlled by the nuclear poly(A)-binding protein regulating the interaction between poly(A) polymerase and the cleavage and polyadenylation specificity factor. J Biol Chem. 2009, Aug, 21;284(34):22803\u201314.","journal-title":"J Biol Chem"},{"issue":"18","key":"4313_CR14","doi-asserted-by":"publisher","first-page":"9089","DOI":"10.1093\/nar\/gks655","volume":"40","author":"de Klerk E","year":"2012","unstructured":"de Klerk E, Venema A, Anvar SY, Goeman JJ, Hu O, Trollet C, et al. Poly(A) binding protein nuclear 1 levels affect alternative polyadenylation. Nucleic Acids Res. 2012, Oct;40(18):9089\u2013101.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"4313_CR15","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.cell.2012.03.022","volume":"149","author":"M Jenal","year":"2012","unstructured":"Jenal M, Elkon R, Loayza-Puch F, Van Haaften G, K\u00fchn U, Menzies FM, et al. The poly(A)-binding protein nuclear 1 suppresses alternative cleavage and polyadenylation sites. Cell. 2012;149(3):538\u201353.","journal-title":"Cell"},{"issue":"3","key":"4313_CR16","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/NEN.0b013e3182854c07","volume":"72","author":"T Gidaro","year":"2013","unstructured":"Gidaro T, Negroni E, Peri\u00e9 S, Mirabella M, Lain\u00e9 J, Lacau St Guily J, et al. Atrophy, fibrosis, and increased PAX7-positive cells in pharyngeal muscles of oculopharyngeal muscular dystrophy patients. J Neuropathol Exp Neurol. 2013, Mar;72(3):234\u201343.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4","key":"4313_CR17","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/ene.14131","volume":"27","author":"V Galimberti","year":"2020","unstructured":"Galimberti V, Tironi R, Lerario A, Scali M, Del Bo R, Rodolico C, et al. Value of insoluble PABPN1 accumulation in the diagnosis of oculopharyngeal muscular dystrophy. Eur J Neurol. 2020, Apr;27(4):709\u201315.","journal-title":"Eur J Neurol"},{"issue":"OCT","key":"4313_CR18","first-page":"1","volume":"6","author":"Y Raz","year":"2014","unstructured":"Raz Y, Raz V. Oculopharyngeal muscular dystrophy as a paradigm for muscle aging. Front Aging Neurosci. 2014;6(OCT):1\u20135.","journal-title":"Front Aging Neurosci"},{"issue":"6","key":"4313_CR19","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.nmd.2013.03.001","volume":"23","author":"V Raz","year":"2013","unstructured":"Raz V, Butler-Browne G, van Engelen B, Brais B. 191st ENMC international workshop: recent advances in oculopharyngeal muscular dystrophy research: from bench to bedside 8\u201310 June 2012, Naarden, the Netherlands. Neuromuscul Disord NMD. 2013, Jun;23(6):516\u201323.","journal-title":"Neuromuscul Disord NMD"},{"key":"4313_CR20","doi-asserted-by":"crossref","unstructured":"Blumen SC, Nisipeanu P, Sadeh M, Asherov A, Blumen N, Wirguin Y, et al. Epidemiology and inheritance of oculopharyngeal muscular dystrophy in Israel. Neuromuscul Disord. 1997, Oct;7:S38\u201340.","DOI":"10.1016\/S0960-8966(97)00080-1"},{"issue":"1","key":"4313_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/1531-8249(199907)46:1<115::AID-ANA17>3.0.CO;2-O","volume":"46","author":"SC Blumen","year":"1999","unstructured":"Blumen SC, Brais B, Korczyn AD, Medinsky S, Chapman J, Asherov A, et al. Homozygotes for oculopharyngeal muscular dystrophy have a severe form of the disease. Ann Neurol. 1999;46(1):115\u201318.","journal-title":"Ann Neurol"},{"issue":"9","key":"4313_CR22","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1212\/WNL.55.9.1267","volume":"55","author":"SC Blumen","year":"2000","unstructured":"Blumen SC, Korczyn AD, Lavoie H, Medynski S, Chapman J, Asherov A, et al. Oculopharyngeal MD among Bukhara Jews is due to a founder (GCG)9 mutation is in the PABP2 gene. Neurology. 2000;55(9):1267\u201370.","journal-title":"Neurology"},{"issue":"5\u20136","key":"4313_CR23","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/0960-8966(93)90119-5","volume":"3","author":"SC Blumen","year":"1993","unstructured":"Blumen SC, Nisipeanu P, Sadeh M, Asherov A, Tom\u00e9 FM, Korczyn AD. Clinical features of oculopharyngeal muscular dystrophy among Bukhara Jews. Neuromuscul Disord NMD. 1993, Jan;3(5\u20136):575\u201377.","journal-title":"Neuromuscul Disord NMD"},{"issue":"3","key":"4313_CR24","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/hmg\/4.3.429","volume":"4","author":"B Brais","year":"1995","unstructured":"Brais B, Xie YG, Sanson M, Morgan K, Weissenbach J, Korczyn AD, et al. The oculopharyngeal muscular dystrophy locus maps to the region of the cardiac alpha and beta myosin heavy chain genes on chromosome 14q11.2-q13. Hum Mol Genet. 1995, Mar;4(3):429\u201334.","journal-title":"Hum Mol Genet"},{"issue":"19","key":"4313_CR25","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1001\/jama.286.19.2437","volume":"286","author":"MW Becher","year":"2001","unstructured":"Becher MW, Morrison L, Davis LE, Maki WC, King MK, Bicknell JM, et al. Oculopharyngeal muscular dystrophy in Hispanic New Mexicans. JAMA. 2001, Nov, 21;286(19):2437\u201340.","journal-title":"JAMA"},{"issue":"5","key":"4313_CR26","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1111\/ene.15252","volume":"29","author":"J Alonso-P\u00e9rez","year":"2022","unstructured":"Alonso-P\u00e9rez J, de Le\u00f3n Hern\u00e1ndez JC, P\u00e9rez-P\u00e9rez H, Mendoza-Grim\u00f3n MD, Gutierrez-Martinez AJ, Hadjigeorgiou I, et al. Clinical and genetic features of a large homogeneous cohort of oculopharyngeal muscular dystrophy patients from the Canary Islands. Eur J Neurol. 2022, May;29(5):1488\u201395.","journal-title":"Eur J Neurol"},{"key":"4313_CR27","doi-asserted-by":"crossref","unstructured":"Stern JE, Zvulunov A, Dori A, Charas H, Benyamini L, Simon GB, et al. The national Israeli registry for oculo-pharyngeal muscular dystrophy (IsrO-PMD): rationale and design. J Rare Dis [Internet]. 2023, Nov, 1;2(1). Available from: https:\/\/link.springer.com\/10.1007\/s44162-023-00020-z. cited 2025 May 1.","DOI":"10.1007\/s44162-023-00020-z"},{"issue":"8","key":"4313_CR28","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/j.apmr.2004.11.049","volume":"86","author":"MA Crary","year":"2005","unstructured":"Crary MA, Mann GDC, Groher ME. Initial psychometric assessment of a Functional oral Intake scale for dysphagia in stroke patients. Arch Phys Med Rehabil. 2005, Aug;86(8):1516\u201320.","journal-title":"Arch Phys Med Rehabil"},{"issue":"3","key":"4313_CR29","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/mus.26779","volume":"61","author":"L Greenbaum","year":"2020","unstructured":"Greenbaum L, Barel O, Nikitin V, Hersalis-Eldar A, Kol N, Reznik-Wolf H, et al. Identification of a homozygous VRK1 mutation in two patients with adult-onset distal hereditary motor neuropathy. Muscle Nerve. 2020, Mar, 16;61(3):395\u2013400.","journal-title":"Muscle Nerve"},{"key":"4313_CR30","doi-asserted-by":"crossref","unstructured":"Mekiten O, Zvulunov A, Ben Simon G, Charas H, Ben-David M, Shelly S, et al. Ocular manifestations and outcomes of OPMD- a report from the national IsrOPMD registry. Eur J Ophthalmol. 2024 May 29;11206721241259145.","DOI":"10.1177\/11206721241259145"},{"issue":"November 2023","key":"4313_CR31","doi-asserted-by":"publisher","first-page":"123074","DOI":"10.1016\/j.jns.2024.123074","volume":"463","author":"N Lempel","year":"2024","unstructured":"Lempel N, Shelly S, Chorin O, Rock R, Eliyahu A, Finezilber Y, et al. The yield of genetic workup for middle-aged and elderly patients with neurological disorders in a real-world setting. J Neurol Sci. 2024;463(November 2023):123074.","journal-title":"J Neurol Sci"},{"issue":"5","key":"4313_CR32","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1136\/jnnp-2018-319578","volume":"90","author":"A Alonso-Jimenez","year":"2019","unstructured":"Alonso-Jimenez A, Rhmjm K, Alejaldre-Monforte A, Nu\u00f1ez-Peralta C, Horlings CGC, van Engelen BGM, et al. Muscle MRI in a large cohort of patients with oculopharyngeal muscular dystrophy. J Neurol, Neurosurg Psychiatry. 2019, May;90(5):576\u201385.","journal-title":"J Neurol, Neurosurg Psychiatry"},{"issue":"2","key":"4313_CR33","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/ane.12244","volume":"130","author":"N Witting","year":"2014","unstructured":"Witting N, Mensah A, K\u00f8ber L, Bundgaard H, Petri H, Duno M, et al. Ocular, bulbar, limb, and cardiopulmonary involvement in oculopharyngeal muscular dystrophy. Acta Neurol Scand. 2014, Aug;130(2):125\u201330.","journal-title":"Acta Neurol Scand"},{"issue":"12","key":"4313_CR34","first-page":"748","volume":"15","author":"SC Blumen","year":"2013","unstructured":"Blumen SC, Kesler A, Dabby R, Shalev S, Khayat M, Almog Y, et al. Oculopharyngeal muscular dystrophy among Bulgarian Jews: a new cluster? Isr Med Assoc J IMAJ. 2013, Dec;15(12):748\u201352.","journal-title":"Isr Med Assoc J IMAJ"},{"issue":"8","key":"4313_CR35","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1007\/s00415-011-6374-5","volume":"259","author":"M Tondo","year":"2012","unstructured":"Tondo M, G\u00e1mez J, Guti\u00e9rrez-Rivas E, Medel-Jim\u00e9nez R, Martorell L. Genotype and phenotype study of 34 Spanish patients diagnosed with oculopharyngeal muscular dystrophy. J Neurol. 2012, Aug;259(8):1546\u201352.","journal-title":"J Neurol"},{"issue":"2","key":"4313_CR36","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1152\/physiolgenomics.00158.2022","volume":"55","author":"B Coyle-Asbil","year":"2023","unstructured":"Coyle-Asbil B, Ogilvie LM, Simpson JA. Emerging roles for estrogen in regulating skeletal muscle physiology. Physiol Genomics. 2023, Feb, 1;55(2):75\u201378.","journal-title":"Physiol Genomics"},{"key":"4313_CR37","doi-asserted-by":"publisher","first-page":"111793","DOI":"10.1016\/j.mad.2023.111793","volume":"211","author":"C Vinciguerra","year":"2023","unstructured":"Vinciguerra C, Iacono S, Bevilacqua L, Landolfi A, Piscosquito G, Ginanneschi F, et al. Sex differences in neuromuscular disorders. Mech Ageing Dev. 2023, Apr;211:111793.","journal-title":"Mech Ageing Dev"},{"key":"4313_CR38","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/978-3-319-70178-3_9","volume":"1043","author":"LJ Anderson","year":"2017","unstructured":"Anderson LJ, Liu H, Garcia JM. Sex differences in muscle wasting. Adv Exp Med Biol. 2017;1043:153\u201397.","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"4313_CR39","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/mus.20726","volume":"35","author":"A Semmler","year":"2007","unstructured":"Semmler A, Kress W, Vielhaber S, Schr\u00f6der R, Kornblum C. Variability of the recessive oculopharyngeal muscular dystrophy phenotype. Muscle Nerve. 2007, May;35(5):681\u201384.","journal-title":"Muscle Nerve"},{"issue":"2","key":"4313_CR40","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.otohns.2006.03.015","volume":"135","author":"C Laurent","year":"2006","unstructured":"Laurent C, Sophie P, Pascal L, Bruno E, Jean Lacau St G. Long-term results of cricopharyngeal myotomy in oculopharyngeal muscular dystrophy. Otolaryngol Neck Surg. 2006, Aug;135(2):218\u201322.","journal-title":"Otolaryngol Neck Surg"},{"key":"4313_CR41","doi-asserted-by":"crossref","unstructured":"Alungulese AL, Garc\u00eda Soldevilla MA, Gordo Ma\u00f1as R, Vidal D\u00edaz MB. Oculopharyngeal muscular dystrophy coexisting with myasthenia gravis. Pract Neurol. 2022 May 9;practneurol-2022-003429.","DOI":"10.1136\/practneurol-2022-003429"},{"issue":"5","key":"4313_CR42","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00415-011-6255-y","volume":"259","author":"R Dubbioso","year":"2012","unstructured":"Dubbioso R, Moretta P, Manganelli F, Fiorillo C, Iodice R, Trojano L, et al. Executive functions are impaired in heterozygote patients with oculopharyngeal muscular dystrophy. J Neurol. 2012, May;259(5):833\u201337.","journal-title":"J Neurol"},{"issue":"1","key":"4313_CR43","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/mt.2013.155","volume":"22","author":"S P\u00e9ri\u00e9","year":"2014","unstructured":"P\u00e9ri\u00e9 S, Trollet C, Mouly V, Vanneaux V, Mamchaoui K, Bouazza B, et al. Autologous myoblast transplantation for oculopharyngeal muscular dystrophy: a phase I\/IIa clinical study. Mol Ther J Am Soc Gene Ther. 2014, Jan;22(1):219\u201325.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"issue":"6","key":"4313_CR44","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/nm1242","volume":"11","author":"JE Davies","year":"2005","unstructured":"Davies JE, Wang L, Garcia-Oroz L, Cook LJ, Vacher C, O\u2019Donovan DG, et al. Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Nat Med. 2005, Jun;11(6):672\u201377.","journal-title":"Nat Med"},{"issue":"1","key":"4313_CR45","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/emmm.201000109","volume":"3","author":"N Barbezier","year":"2011","unstructured":"Barbezier N, Chartier A, Bidet Y, Buttstedt A, Voisset C, Galons H, et al. Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy. EMBO Mol Med. 2011, Jan;3(1):35\u201349.","journal-title":"EMBO Mol Med"},{"key":"4313_CR46","doi-asserted-by":"crossref","unstructured":"Malerba A, Klein P, Bachtarzi H, Jarmin SA, Cordova G, Ferry A, et al. PABPN1 gene therapy for oculopharyngeal muscular dystrophy. Nat Commun. 2017;8.","DOI":"10.1038\/ncomms14848"},{"issue":"24","key":"4313_CR47","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.omtn.2021.02.017","volume":"4","author":"V Strings-Ufombah","year":"2021","unstructured":"Strings-Ufombah V, Malerba A, Kao SC, Harbaran S, Roth F, Cappellari O, et al. BB-301: a silence and replace AAV-based vector for the treatment of oculopharyngeal muscular dystrophy. Mol Ther Nucleic Acids. 2021, Jun;4(24):67\u201378.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"5","key":"4313_CR48","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/jcsm.12438","volume":"10","author":"P Harish","year":"2019","unstructured":"Harish P, Malerba A, Lu-Nguyen N, Forrest L, Cappellari O, Roth F, et al. Inhibition of myostatin improves muscle atrophy in oculopharyngeal muscular dystrophy (OPMD). J Cachexia, Sarcopenia Muscle. 2019, Oct;10(5):1016\u201326.","journal-title":"J Cachexia, Sarcopenia Muscle"},{"issue":"5","key":"4313_CR49","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1089\/hum.2015.014","volume":"26","author":"P Harish","year":"2015","unstructured":"Harish P, Malerba A, Dickson G, Bachtarzi H. Progress on gene therapy, cell therapy, and pharmacological strategies toward the treatment of oculopharyngeal muscular dystrophy. Hum Gene Ther. 2015, May;26(5):286\u201392.","journal-title":"Hum Gene Ther"},{"issue":"11","key":"4313_CR50","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.nmd.2023.09.010","volume":"33","author":"IC Smith","year":"2023","unstructured":"Smith IC, Chakraborty S, Bourque PR, Sampaio ML, Melkus G, Lochm\u00fcller H, et al. Emerging and established biomarkers of oculopharyngeal muscular dystrophy. Neuromuscul Disord NMD. 2023, Nov;33(11):824\u201334.","journal-title":"Neuromuscul Disord NMD"},{"issue":"17","key":"4313_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21176059","volume":"21","author":"V Raz","year":"2020","unstructured":"Raz V, Rhmjm K, Mei H, Riaz M, Buermans H, Lassche S, et al. Age-associated salivary microRNA biomarkers for oculopharyngeal muscular dystrophy. Int J Mol Sci. 2020;21(17):1\u201315.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"4313_CR52","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3390\/metabo13060769","volume":"13","author":"P Harish","year":"2023","unstructured":"Harish P, Malerba A, Rhmjm K, Shademan M, van Engelan B, Raz V, et al. Novel metabolomic approach for identifying pathology-specific biomarkers in rare diseases: a case study in oculopharyngeal muscular dystrophy (OPMD). Metabolites. 2023, Jun, 19;13(6):769.","journal-title":"Metabolites"},{"key":"4313_CR53","doi-asserted-by":"crossref","unstructured":"Smith IC, Sampaio ML, Melkus G, Meier-Ross K, Chakraborty S, Stotts C, et al. Plasma-derived protein and imaging biomarkers distinguish disease severity in oculopharyngeal muscular dystrophy. J Neuromuscul Dis. 2024 Dec 20;22143602241304990.","DOI":"10.1177\/22143602241304990"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04313-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04313-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04313-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:00:53Z","timestamp":1781650853000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04313-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4313"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04313-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The SMC Institutional Review Board approved the study in accordance with the Declaration of Helsinki (8801\u201321-SMC). All participants provided written informed consent. The study was registered at ClinicalTrials.gov: ID NCT07146256; Study Start 2022\u201302-01.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The manuscript contains no individual data. Therefore, in addition to informed consent for participation in the study, no further consent was required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"203"}}